The doctoral dissertation was a series of three publications describing: a survey among members of the Polish Society Supporting People with Inflammatory Bowel Diseases “J-elita” with Crohn's disease, a study of the medical resources utilization among patients with Crohn's disease treated with biological drugs in Poland (analysis of the database of the National Health Fund) and the economic evaluation of the use of vedolizumab and ustekinumab after failure of the treatment with a tumour necrosis factor-alpha (TNFα) antagonist in Poland. The results of the survey among 200 patients from Poland and the study of the medical resources utilization among 1,393 patients using biological drugs in Poland allowed to determine the input data of the economic analysis (utility weights, direct non-medical costs, indirect costs, direct medical costs) and confirmed some of the assumptions made as part of the analysis economic, including, the validity of taking into account the difference in direct and indirect costs between the clinical states of the economic model. The modelling carried out as part of the economic analysis allowed to reliably reflect the treatment pathway and the course of the Crohn's disease in clinical practice. The results of the economic analysis suggested that the use of ustekinumab or vedolizumab after failure of therapy with TNFα antagonists is cost-effective in Pola ; nd. The replacement of the TNFα antagonist with ustekinumab or vedolizumab in the second-line treatment and the course of the disease after discontinuation of biologics were the most important aspects influencing the conclusion.
choroby układu trawiennego ; farmakologia
Rada Dyscypliny Nauki o zdrowiu
25 mar 2024
24 sty 2023
89
36
http://dl.cm-uj.krakow.pl:8080/publication/4929
Nazwa wydania | Data |
---|---|
ZB-135519 | 25 mar 2024 |
Holko, Przemysław
Szczeklik, Katarzyna
Herman, Roma
Brzozowski, Bartosz
Rozpondek, Piotr
Wasilewska, Agata
Kaczmarczyk, Olga
Cegielny, Tomasz